Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Lijuan Chen, Yuyao Yi et al.|Clinical Cancer Research|2019Cited by 19
[Immunophenotype of acute leukemia and its clinical significance].Huanling Zhu, Lei Song, Ting Niu et al.|PubMed|2002Cited by 7